Updates are available Correction dated 2019-05-23
Click to view Correction: https://doi.org/10.1186/s12885-019-5699-9
-
Authors
Li, Chen
Wang, Xiaomin
Wang, Xin
Han, Chun
Wang, Ping
Pang, Qingsong
Chen, Junqiang
Sun, Xinchen
Wang, Lan
Zhang, Wencheng
Lin, Yu
Ge, Xiaolin
Zhou, Zongmei
Ni, Wenjie
Chang, Xiao
Liang, Jun
Deng, Lei
Wang, Wenqing
Zhao, Yidian
Xiao, Zefen http://orcid.org/0000-0003-0503-6814
-
Funding
Funding for this research was provided by:
Beijing Hope Run Special Fund of Cancer Foundation of China (LC2016L04)
National Key Projects of Research and Development of China (2016YFC0904600)
- License Information
-
More Information
Article History
Received: 25 November 2018
Accepted: 28 March 2019
First Online: 29 April 2019
Change Date: 23 May 2019
Change Type: Correction
Change Details: Following publication of the original article [1], the authors reported that an error in the Methods/Design, Study design and objectives section (third sentence).
Ethics approval and consent to participate
: Institutional review board approval was obtained for the 3JECROG P-01 trial from the ethical committee of the Chinese Academy of Medical Sciences (reference number NCC2016 YL-06), of Anyang Cancer Hospital (AZLL 022017002170116), of Tianjin Cancer Hospital (E2018309), of Fujian Cancer Hospital (SQ2019–037-01). The 3JECROG P-01 trial is published under NCT02979691 onExternalRef removed. Written informed consent is obtained from all participants.
: Not applicable.
: The authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
